Related Experiment Videos
TIGR/MYOC gene sequence alterations in individuals with and without primary open-angle glaucoma
Chi Pui Pang1, Yuk Fai Leung, Baojian Fan
1Department of Ophthalmology and Visual Sciences, the Chinese University of Hong Kong, Hong Kong, China. cppang@cuhk.edu.hk
Investigative Ophthalmology & Visual Science
|October 3, 2002
Summary
Researchers identified novel TIGR/MYOC gene variants in Chinese primary open-angle glaucoma (POAG) patients. Some variants may be protective, while others appear disease-associated, offering insights into POAG genetics.
Area of Science:
- Ophthalmology
- Genetics
- Molecular Biology
Background:
- Primary open-angle glaucoma (POAG) is a leading cause of irreversible blindness worldwide.
- The TIGR/MYOC gene, encoding myocilin, is a known contributor to glaucoma pathogenesis.
- Understanding genetic variations in TIGR/MYOC is crucial for diagnosing and potentially treating POAG, especially in diverse ethnic populations.
Purpose of the Study:
- To identify sequence alterations in the TIGR/MYOC gene associated with POAG in a Chinese cohort.
- To investigate the potential role of identified variants in POAG development and progression.
Main Methods:
- Screening of 201 unrelated Chinese POAG patients and 291 control subjects for TIGR/MYOC gene alterations.
- Utilizing polymerase chain reaction, conformation sensitive gel electrophoresis, and DNA sequencing for variant detection.
- Further screening of additional control subjects for specific identified alterations.
Main Results:
- Fourteen sequence variants leading to amino acid changes were identified, with seven being novel.
- Novel variants Glu300Lys and Tyr471Cys were exclusively found in POAG patients.
- The Arg46Stop variant occurred at similar frequencies in both POAG patients and controls, with no significant impact on intraocular pressure (IOP).
Conclusions:
- The Gly12Arg variant may confer a protective effect against POAG in the studied population.
- A potential disease-causing TIGR/MYOC mutation frequency of 1.5% was estimated in POAG patients.
- The Arg46Stop variant's prevalence suggests it does not significantly alter glaucoma risk, despite predicted protein truncation.